FRANKFURT (Reuters) -German generic drugmaker Stada is reviving plans to go public during the autumn if market conditions are supportive, its CEO told news agency dpa on Thursday.
“We are preparing an IPO in the autumn, provided the general conditions are right,” Peter Goldschmidt was quoted as saying.
Financial advisers told Reuters last month they view Stada as a candidate for an initial public offering during the second half, alongside prosthetics maker Ottobock, Deutsche Boerse’s research and technology unit ISS Stoxx and classifieds business Swiss Marketplace Group.
Stada, held by private equity firms Bain Capital and Cinven, has previously said it was deliberating with its investors all options regarding future ownership, including an IPO and a sale.
Also on Thursday, Stada reported that first-half earnings before interest, tax, depreciation, amortization (EBITDA) and one-off items rose a currency-adjusted 5% to 481 million euros ($563 million).
Initial IPO plans were put on hold in March.
($1 = 0.8542 euros)
(Reporting by Ludwig Burger, editing by Thomas Seythal)
Comments